Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

Overview

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Full Title of Study: “The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 2017

Detailed Description

Selection of Study Population: The study will enroll 60 adult subjects with transfusion dependent thalassemia receiving deferasirox iron chelation therapy. All eligible subjects will be asked to provide informed consent before participating in the study. Randomization: Subjects will be randomized in a 1:1 ratio to either continuation of their DFX (control arm) or a combination of DFX plus amlodipine (amlodipine arm). Treatment: Subjects randomized to the amlodipine arm will receive open label medication (amlodipine) starting at 2.5mg/day and up-titrated by 2.5mg every 7-14 days with the goal of reaching 10mg/day. DFX dose in either arm will not be adjusted unless it was deemed unsafe to remain on the same dose of DFX by the treating physician (significant side effects, lack of efficacy or over-chelation) or T2* drops below 8 ms. Safety Assessment: Weekly or fortnightly amlodipine titration will be conducted by the research physician in-clinic, based on blood pressure, tolerability, and presence or absence of side-effects. Adverse Events will be assessed at every visit after the first dose through to the last subject visit. Efficacy Assessment: the efficacy of amlodipine combined to standard chelation therapy will be assessed by cardiac T2*MRI, done at baseline and 12 months post treatment.

Interventions

  • Drug: Amlodipine
    • amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
  • Drug: Deferasirox
    • Deferasirox administered per standard of care by the treating physician

Arms, Groups and Cohorts

  • Active Comparator: Deferasirox
    • deferasirox iron chelation therapy and standard of care by the treating physician
  • Experimental: Deferasirox plus amlodipine
    • deferasirox iron chelation therapy with amlodipine

Clinical Trial Outcome Measures

Primary Measures

  • Change in cardiac T2*
    • Time Frame: 12 months following randomization
    • Change in cardiac T2* as determined by MRI

Secondary Measures

  • Change in left ventricular ejection fraction
    • Time Frame: 12 months following randomization
    • Change in left ventricular ejection fraction (in %) as determined by MRI
  • Number of Participants with Adverse Events
    • Time Frame: 12 months following randomization

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of transfusion-dependent Thalassemia being followed by a thalassemia comprehensive care clinic Age 18 or older – Taking deferasirox and on a stable dose for >3 months – Evidence on cardiac MRI of mild to moderate cardiac iron overload (T2*<20ms but ≥10ms) as measured within 3 months prior to randomization. If a recent cardiac MRI has not been obtained, patients who otherwise meet all eligibility criteria and provide appropriate consent will undergo a cardiac MRI to confirm eligibility – Preserved left ventricular ejection fraction (LVEF) >55% as measured by cardiac MRI. If a recent cardiac MRI has not been obtained, patients who otherwise meet all eligibility criteria and provide appropriate consent will undergo a cardiac MRI to confirm eligibility. – Agreeable to use an approved method of contraception if female of childbearing potential for the entire duration of the study. Exclusion Criteria:

  • Serum ferritin < 500 ng/mL at screening – Liver iron concentration > 30 mg/g dw as measured by liver R2 MRI (FerriScan) – Congestive heart failure – Severe refractory Hypotension (less than 90 mmHg systolic) – Currently taking any calcium channel blockers – Pregnancy or nursing (a negative HCG (pregnancy) test must be obtained prior to randomization) – As a result of medical review, physical examination or screening investigations, the Principal Investigator (PI) considers the subject unfit for the study – No fixed address – Hypersensitivity to amlodipine or other dihydropyridines

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kevin H.M. Kuo, MD, MSc, FRCPC
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Kevin H.M. Kuo, MD, MSc, FRCPC, Assistant Professor – University Health Network, Toronto
  • Overall Official(s)
    • Kevin HM Kuo, MD MSc FRCPC, Principal Investigator, University Health Network, Toronto
  • Overall Contact(s)
    • Rebecca Leroux, RN, CCRP, +1-416-715-6485, rebecca.leroux@uhn.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.